NCT04652661View on ClinicalTrials.gov

Intranasal Dexmedetomidine Versus Intranasal Midazolam for MRI In Pediatrics

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions
DexmedetomidineMidazolamMRIPediatrics
Interventions
DRUG

Dexmedetomidine

30 children will be sedated with 2 μg/kg intranasal DEX.

DRUG

Midazolam

30 children will be sedated with 0.3 mg/kg intranasal midazolam.

Trial Locations (1)

31527

Tanta University Hospitals, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT04652661 - Intranasal Dexmedetomidine Versus Intranasal Midazolam for MRI In Pediatrics | Biotech Hunter | Biotech Hunter